The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...

In Tuesday's pre-market trade, Pfizer's ( PEE, Financial) shares edged up following a strong third-quarter earnings report ...

Pfizer Inc ( (PFE) ) has realeased its Q3 earnings. Here is a breakdown of the information Pfizer Inc presented to its investors. Pfizer Inc., ...

Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...

Shares of Pfizer (PFE) initially rose slightly after markets reacted to the firm’s quarterly results. By the end of the day yesterday, PFE stock lost 1.39%. Pfizer reported topline growth of $2.8 ...

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist ...

Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Strip out the Covid product gains and Pfizer’s predicament is unchanged. It is struggling to convince investors there is life ...